Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Growth in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 800 shares, a growth of 700.0% from the March 31st total of 100 shares. Based on an average daily trading volume, of 12,900 shares, the days-to-cover ratio is currently 0.1 days.

Bavarian Nordic A/S Price Performance

Shares of Bavarian Nordic A/S stock traded down $0.23 during midday trading on Thursday, hitting $6.92. 4,115 shares of the company were exchanged, compared to its average volume of 5,781. The firm has a 50 day simple moving average of $7.61 and a 200-day simple moving average of $7.59. Bavarian Nordic A/S has a 52 week low of $5.95 and a 52 week high of $10.65. The firm has a market cap of $1.62 billion, a P/E ratio of 7.53 and a beta of 1.50.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.12. Bavarian Nordic A/S had a return on equity of 0.07% and a net margin of 20.80%. The firm had revenue of $353.27 million during the quarter, compared to the consensus estimate of $340.71 million. Equities research analysts expect that Bavarian Nordic A/S will post 0.52 earnings per share for the current year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.